Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Citizens
August 6, 2026 6:31 AM
Citizens analyst Jonathan Wolleben lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $137.00 (from $146.00) while maintaining a Market Outperform rating.
